<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]>
<us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20260345831A1-20261105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20261019" date-publ="20261105">
<us-bibliographic-data-application lang="EN" country="US">
<publication-reference>
<document-id>
<country>US</country>
<doc-number>20260345831</doc-number>
<kind>A1</kind>
<date>20261105</date>
</document-id>
</publication-reference>
<application-reference appl-type="utility">
<document-id>
<country>US</country>
<doc-number>19701916</doc-number>
<date>20260609</date>
</document-id>
</application-reference>
<us-application-series-code>19</us-application-series-code>
<classifications-ipcr>
<classification-ipcr>
<ipc-version-indicator><date>20060101</date></ipc-version-indicator>
<classification-level>A</classification-level>
<section>A</section>
<class>61</class>
<subclass>K</subclass>
<main-group>48</main-group>
<subgroup>00</subgroup>
<symbol-position>F</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20261105</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
</classification-ipcr>
<classification-ipcr>
<ipc-version-indicator><date>20060101</date></ipc-version-indicator>
<classification-level>A</classification-level>
<section>C</section>
<class>12</class>
<subclass>N</subclass>
<main-group>15</main-group>
<subgroup>11</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20261105</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
</classification-ipcr>
</classifications-ipcr>
<classifications-cpc>
<main-cpc>
<classification-cpc>
<cpc-version-indicator><date>20130101</date></cpc-version-indicator>
<section>A</section>
<class>61</class>
<subclass>K</subclass>
<main-group>48</main-group>
<subgroup>0066</subgroup>
<symbol-position>F</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20261105</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
<scheme-origination-code>C</scheme-origination-code>
</classification-cpc>
</main-cpc>
<further-cpc>
<classification-cpc>
<cpc-version-indicator><date>20130101</date></cpc-version-indicator>
<section>A</section>
<class>61</class>
<subclass>K</subclass>
<main-group>48</main-group>
<subgroup>0033</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20261105</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
<scheme-origination-code>C</scheme-origination-code>
</classification-cpc>
<classification-cpc>
<cpc-version-indicator><date>20130101</date></cpc-version-indicator>
<section>C</section>
<class>12</class>
<subclass>N</subclass>
<main-group>15</main-group>
<subgroup>11</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20261105</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
<scheme-origination-code>C</scheme-origination-code>
</classification-cpc>
<classification-cpc>
<cpc-version-indicator><date>20170501</date></cpc-version-indicator>
<section>C</section>
<class>12</class>
<subclass>N</subclass>
<main-group>2310</main-group>
<subgroup>20</subgroup>
<symbol-position>L</symbol-position>
<classification-value>A</classification-value>
<action-date><date>20261105</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
<scheme-origination-code>C</scheme-origination-code>
</classification-cpc>
</further-cpc>
</classifications-cpc>
<invention-title id="ID0ENB">RNA-GUIDED CONTROL OF PROTEIN SECRETION AND MEMBRANE PROTEIN EXPRESSION</invention-title>
<us-related-documents>
<continuation>
<relation>
<parent-doc>
<document-id>
<country>US</country>
<doc-number>PCT/US2025/014154</doc-number>
<date>20250131</date>
</document-id>
<parent-status>PENDING</parent-status>
</parent-doc>
<child-doc>
<document-id>
<country>US</country>
<doc-number>19701916</doc-number>
</document-id>
</child-doc>
</relation>
</continuation>
<us-provisional-application>
<document-id>
<country>US</country>
<doc-number>63627314</doc-number>
<date>20240131</date>
</document-id>
</us-provisional-application>
</us-related-documents>
<us-parties>
<us-applicants>
<us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee">
<addressbook>
<orgname>THE UNIVERSITY OF CHICAGO</orgname>
<address>
<city>Chicago</city>
<state>IL</state>
<country>US</country>
</address>
</addressbook>
<residence>
<country>US</country>
</residence>
</us-applicant>
</us-applicants>
<inventors>
<inventor sequence="00" designation="us-only">
<addressbook>
<last-name>HE</last-name>
<first-name>Chuan</first-name>
<address>
<city>Chicago</city>
<state>IL</state>
<country>US</country>
</address>
</addressbook>
</inventor>
<inventor sequence="01" designation="us-only">
<addressbook>
<last-name>PAN</last-name>
<first-name>Tao</first-name>
<address>
<city>Chicago</city>
<state>IL</state>
<country>US</country>
</address>
</addressbook>
</inventor>
<inventor sequence="02" designation="us-only">
<addressbook>
<last-name>LIU</last-name>
<first-name>Bei</first-name>
<address>
<city>Chicago</city>
<state>IL</state>
<country>US</country>
</address>
</addressbook>
</inventor>
</inventors>
</us-parties>
<assignees>
<assignee>
<addressbook>
<orgname>THE UNIVERSITY OF CHICAGO</orgname>
<role>02</role>
<address>
<city>Chicago</city>
<state>IL</state>
<country>US</country>
</address>
</addressbook>
</assignee>
</assignees>
</us-bibliographic-data-application>
<abstract id="abstract">
<p id="p-0001" num="0000">Aspects of the disclosure relate to nucleic acid compositions involving small nucleolar RNAs (snoRNAs), including for increasing secretion of a protein of interest. Aspects also relate to methods of using the nucleic acid compositions.</p>
</abstract>
<us-sequence-list-doc id="SEQLST-1">
<sequence-list file="US20260345831A1-20261105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.26"/>
</us-sequence-list-doc>
<us-claim-statement>What is claimed is:</us-claim-statement>
<claims id="claims">
<claim id="CLM-00001" num="00001">
<claim-text><b>1</b>. A recombinant nucleic acid encoding a protein of interest, the nucleic acid comprising a recombinant SNORA73A binding motif.</claim-text>
</claim>
<claim id="CLM-00002" num="00002">
<claim-text><b>2</b>. The recombinant nucleic acid of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the SNORA73A binding motif comprises a nucleic acid sequence comprising GAGGCCCA.</claim-text>
</claim>
<claim id="CLM-00003" num="00003">
<claim-text><b>3</b>. The recombinant nucleic acid of <claim-ref idref="CLM-00001 CLM-00002">claim 1 or 2</claim-ref>, wherein a wildtype nucleic acid encoding the protein of interest does not comprise the SNORA73A binding motif.</claim-text>
</claim>
<claim id="CLM-00004" num="00004">
<claim-text><b>4</b>. The recombinant nucleic acid of any one of <claim-ref idref="CLM-00001 CLM-00002 CLM-00003">claims 1 to 3</claim-ref>, wherein the protein of interest comprises a therapeutic protein.</claim-text>
</claim>
<claim id="CLM-00005" num="00005">
<claim-text><b>5</b>. The recombinant nucleic acid of any one of <claim-ref idref="CLM-00001 CLM-00002 CLM-00003 CLM-00004">claims 1 to 4</claim-ref>, wherein the SNORA73A binding motif is at the 3&#x2032; terminus of the recombinant nucleic acid.</claim-text>
</claim>
<claim id="CLM-00006" num="00006">
<claim-text><b>6</b>. A recombinant small nucleolar RNA (snoRNA) comprising a recombinant binding sequence complementary to a sequence on an mRNA encoding a protein of interest.</claim-text>
</claim>
<claim id="CLM-00007" num="00007">
<claim-text><b>7</b>. The recombinant snoRNA of <claim-ref idref="CLM-00006">claim 6</claim-ref>, wherein the sequence on the mRNA is a sequence in the 3&#x2032; UTR of the mRNA.</claim-text>
</claim>
<claim id="CLM-00008" num="00008">
<claim-text><b>8</b>. A method of increasing protein secretion of a protein of interest and/or increasing membrane protein expression of a protein of interest, the method comprising contacting an mRNA encoding the protein of interest with a snoRNA comprising a recombinant binding sequence complementary to a sequence on the mRNA.</claim-text>
</claim>
<claim id="CLM-00009" num="00009">
<claim-text><b>9</b>. A method of increasing cellular protein secretion of a protein of interest and/or membrane protein expression of a protein of interest, the method comprising administering a recombinant nucleic acid encoding the protein of interest, wherein the recombinant nucleic acid comprises a recombinant SNORA73A binding motif.</claim-text>
</claim>
<claim id="CLM-00010" num="00010">
<claim-text><b>10</b>. The method of <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the SNORA73A binding motif comprises a nucleic acid sequence comprising GAGGCCCA.</claim-text>
</claim>
<claim id="CLM-00011" num="00011">
<claim-text><b>11</b>. The method of <claim-ref idref="CLM-00009 CLM-00010">claim 9 or 10</claim-ref>, wherein a wildtype nucleic acid encoding the protein of interest does not comprise the SNORA73A binding motif.</claim-text>
</claim>
<claim id="CLM-00012" num="00012">
<claim-text><b>12</b>. The method of any one of <claim-ref idref="CLM-00009 CLM-00010 CLM-00011">claims 9 to 11</claim-ref>, wherein the SNORA73A binding motif is inserted at the 3&#x2032;-terminus of the recombinant nucleic acid.</claim-text>
</claim>
<claim id="CLM-00013" num="00013">
<claim-text><b>13</b>. A method of decreasing cellular protein secretion of a protein of interest and/or membrane protein expression of a protein of interest, the method comprising removing a SNORA73A binding motif in a nucleic acid encoding the protein of interest.</claim-text>
</claim>
<claim id="CLM-00014" num="00014">
<claim-text><b>14</b>. The method of <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein the SNORA73A binding motif comprises a nucleic acid sequence comprising GAGGCCCA.</claim-text>
</claim>
<claim id="CLM-00015" num="00015">
<claim-text><b>15</b>. The method of any one of <claim-ref idref="CLM-00009 CLM-00010 CLM-00011 CLM-00012 CLM-00013 CLM-00014">claims 9 to 14</claim-ref>, further comprising administering the nucleic acid encoding the protein of interest to a cell.</claim-text>
</claim>
<claim id="CLM-00016" num="00016">
<claim-text><b>16</b>. A method of decreasing cellular protein secretion in a population of cells, the method comprising administering a SNORA73 inhibitor to the population of cells.</claim-text>
</claim>
<claim id="CLM-00017" num="00017">
<claim-text><b>17</b>. A method of treating a disease in a patient, the method comprising administering to the patient the recombinant nucleic acid of any one of <claim-ref idref="CLM-00001 CLM-00002 CLM-00003 CLM-00004 CLM-00005 CLM-00006 CLM-00007">claims 1 to 7</claim-ref>.</claim-text>
</claim>
<claim id="CLM-00018" num="00018">
<claim-text><b>18</b>. The method of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the disease is characterized by a deficiency in the protein of interest.</claim-text>
</claim>
<claim id="CLM-00019" num="00019">
<claim-text><b>19</b>. The method of <claim-ref idref="CLM-00017 CLM-00018">claim 17 or 18</claim-ref>, wherein the disease is characterized by a secretion deficiency in the protein of interest.</claim-text>
</claim>
<claim id="CLM-00020" num="00020">
<claim-text><b>20</b>. A method of treating a disease in a patient, the method comprising administering a cell comprising the recombinant nucleic acid of any one of <claim-ref idref="CLM-00001 CLM-00002 CLM-00003 CLM-00004 CLM-00005 CLM-00006 CLM-00007">claims 1 to 7</claim-ref>.</claim-text>
</claim>
</claims>
</us-patent-application>
<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]>
<sequence-cwu id="SEQLST-1">
<publication-reference>
<document-id>
<country>US</country>
<doc-number>20260345831</doc-number>
<kind>A1</kind>
<date>20261105</date>
</document-id>
</publication-reference>
<number>1</number>
<ST26SequenceListing>
<SequenceTotalQuantity>7</SequenceTotalQuantity>
<SequenceData sequenceIDNumber="1">
<INSDSeq>
<INSDSeq_length/>
<INSDSeq_moltype/>
<INSDSeq_division/>
<INSDSeq_sequence>000</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="2">
<INSDSeq>
<INSDSeq_length/>
<INSDSeq_moltype/>
<INSDSeq_division/>
<INSDSeq_sequence>000</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="3">
<INSDSeq>
<INSDSeq_length>10</INSDSeq_length>
<INSDSeq_moltype>DNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..10</INSDFeature_location>
<INSDFeature_quals>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier>
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_quals>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>gaggcccagc</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="4">
<INSDSeq>
<INSDSeq_length/>
<INSDSeq_moltype/>
<INSDSeq_division/>
<INSDSeq_sequence>000</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="5">
<INSDSeq>
<INSDSeq_length/>
<INSDSeq_moltype/>
<INSDSeq_division/>
<INSDSeq_sequence>000</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="6">
<INSDSeq>
<INSDSeq_length>10</INSDSeq_length>
<INSDSeq_moltype>RNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..10</INSDFeature_location>
<INSDFeature_quals>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other RNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier>
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_quals>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>gctgggcctc</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="7">
<INSDSeq>
<INSDSeq_length>46</INSDSeq_length>
<INSDSeq_moltype>DNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..46</INSDFeature_location>
<INSDFeature_quals>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier>
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_quals>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>tcccagagtcctgtcgacaattactggggagacaaaccatgcagga</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
</ST26SequenceListing>
</sequence-cwu>
